stoxline Quote Chart Rank Option Currency Glossary
  
Mangoceuticals, Inc. (MGRX)
1.64  0.16 (10.81%)    05-22 16:00
Open: 1.46
High: 1.68
Volume: 154,626
  
Pre. Close: 1.48
Low: 1.46
Market Cap: 18(M)
Technical analysis
2025-05-22 4:49:32 PM
Short term     
Mid term     
Targets 6-month :  2.66 1-year :  3.35
Resists First :  2.28 Second :  2.87
Pivot price 1.63
Supports First :  1.32 Second :  1.09
MAs MA(5) :  1.53 MA(20) :  1.65
MA(100) :  2.91 MA(250) :  3.54
MACD MACD :  -0.2 Signal :  -0.3
%K %D K(14,3) :  36.2 D(3) :  31.6
RSI RSI(14): 44
52-week High :  7.66 Low :  1.32
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ MGRX ] has closed below upper band by 49.4%. Bollinger Bands are 66.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.68 - 1.69 1.69 - 1.69
Low: 1.44 - 1.45 1.45 - 1.46
Close: 1.63 - 1.64 1.64 - 1.65
Company Description

Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Headline News

Thu, 15 May 2025
MANGOCEUTICALS, INC. SEC 10-Q Report - TradingView

Fri, 25 Apr 2025
MangoRx Targets $37B Pouch Industry: Acquires Smokeless Tech IP, Lands Former JUUL President - Stock Titan

Fri, 25 Apr 2025
ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector - Newsfile

Fri, 25 Apr 2025
Mangoceuticals Announces Strategic Entry into High Growth - GlobeNewswire

Tue, 22 Apr 2025
Mangoceuticals Disrupts $33B Health Market: 5 Revolutionary Products Including FDA-Approved Treatments - Stock Titan

Tue, 25 Mar 2025
Major Diabetes Market Breakthrough: Mangoceuticals Launches GLP-1 Alternative at Fraction of Cost - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Healthcare Information Services
Shares Out 0 (M)
Shares Float 5 (M)
Held by Insiders 3.63e+006 (%)
Held by Institutions 17.2 (%)
Shares Short 245 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.51e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 264.6 %
Return on Equity (ttm) -62.8 %
Qtrly Rev. Growth 615870 %
Gross Profit (p.s.) -23.14
Sales Per Share -48.1
EBITDA (p.s.) 154455
Qtrly Earnings Growth -4.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 0.93
Stock Dividends
Dividend 0
Forward Dividend 277450
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android